Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 BillionGlobeNewsWire • 09/03/24
Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024GlobeNewsWire • 08/30/24
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® LabelGlobeNewsWire • 08/29/24
Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute PainGlobeNewsWire • 08/21/24
Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South AfricaGlobeNewsWire • 08/09/24
Scilex Holding Company Announces Publication of Its Inaugural Sustainability ReportGlobeNewsWire • 07/24/24
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ DebutBenzinga • 07/03/24
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali CapitalReuters • 07/02/24
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business CombinationGlobeNewsWire • 07/02/24
Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New YorkGlobeNewsWire • 07/02/24
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.GlobeNewsWire • 06/20/24
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)GlobeNewsWire • 06/14/24
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio CompaniesGlobeNewsWire • 06/11/24
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®GlobeNewsWire • 06/11/24
Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.GlobeNewsWire • 06/10/24
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024GlobeNewsWire • 06/06/24
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding CompanyGlobeNewsWire • 05/30/24
Scilex Holding Company Announces it has been Added to the MSCI Global Microcap IndexGlobeNewsWire • 05/24/24
Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding CompanyGlobeNewsWire • 05/24/24
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine ProdGlobeNewsWire • 05/14/24
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common StockGlobeNewsWire • 05/13/24
Scilex Holding Company Announces Closing of $15 Million Registered Direct OfferingGlobeNewsWire • 04/25/24
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other AdGlobeNewsWire • 04/16/24